This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
June 30, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that it intends to release second quarter 2014 financial results on
Tuesday, August 5, 2014, prior to the open of the U.S. financial markets. The Company will host a conference call and webcast at
8:30 a.m. Eastern Time on
Tuesday, August 5, 2014 to discuss its financial results. The dial-in number to access the call is U.S./
Canada (877) 251-7980, International (706) 643-1573, and the Conference ID is 65351447.
A taped replay of the conference call will also be available beginning approximately two hours after the call's conclusion and will remain available through 12:00
midnight Eastern Time on
August 19, 2014. The replay may be accessed by dialing (855) 859-2056 and entering Conference ID# 65351447. From international locations, the replay may be accessed by dialing (404) 537-3406 and entering the same Conference ID#. To access the webcast, go to Actavis' Investor Relations Web site at
http://ir.actavis.com. A replay of the webcast will also be available.
Actavis plc (NYSE: ACT) is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. Actavis has global headquarters in
Dublin, Ireland and U.S. administrative headquarters in
Parsippany, New Jersey, USA.
Actavis develops and manufactures generic, brand, branded generic, legacy brands and Over-the-Counter (OTC) pharmaceutical products and has commercial operations in approximately 60 countries. The Company's North American branded pharmaceuticals business is focused principally in the Women's Health, Urology, Gastroenterology and Dermatology therapeutic categories with a strong pipeline of products in various stages of development. Actavis also has a portfolio of five biosimilar products in development in Women's Health and Oncology. Actavis Global Operations has more than 30 manufacturing and distribution facilities around the world, and includes Anda, Inc., a U.S. pharmaceutical product distributor.